Wednesday, 26 August 2026European Markets

BELUGA Stock Bearish Momentum With A 27% Slide In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of BELUGA (BEL 20: BELU.BR) fell by a staggering 27.42% in 21 sessions from €2.48 to €1.80 at 05:10 EST on Tuesday, following the last session's downward trend. BEL 20 is jumping 0.16% to €3,805.96, after two sequential sessions in a row of gains.

About BELUGA

Beluga NV is a private equity and venture capital firm specializing in investments in mid venture, late venture, middle market, and mature companies. It also invests in growth capital, later stages, and buyouts. The firm invests across all sectors in companies based in Belgium with a focus on the Flanders region. It usually invests between €0.25 million ($0.37 million) and €2.5 million ($3.75 million) in the form of a minority stake in both public and private companies. The firm typically invests in companies with enterprise value between €1 million ($1.50 million) and €250 million ($375.7 million), sales values between €0.25 million ($0.37 million) and €500 million ($751.41 million), and EBITDA values between €1 million ($1.50 million) and €100 million ($150.28 million). The firm sources its capital through the stock market. Beluga NV was founded in 1998 and is based in Ternat, Belgium.

Earnings Per Share

As for profitability, BELUGA has a trailing twelve months EPS of €0.02.

PE Ratio

BELUGA has a trailing twelve months price to earnings ratio of 90. Meaning, the purchaser of the share is investing €90 for every euro of annual earnings.

More news about BELUGA (BELU.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com